

Eric Toussirot

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5376449/eric-toussirot-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

2,245
citations

27
h-index

46
g-index

95
ext. papers

2,654
ext. citations

4.3
avg, IF

5.45
L-index

#	Paper	IF	Citations
85	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma.. <i>Joint Bone Spine</i> , 2022 , 89, 105390	2.9	0
84	The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights. <i>Frontiers in Medicine</i> , 2021 , 8, 782150	4.9	1
83	Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. <i>Rheumatology</i> , 2021 , 60, 2816-2825	3.9	3
82	Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2021 , 48, 1888-1889	4.1	0
81	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. <i>RMD Open</i> , 2021 , 7, e001698	5.9	1
80	Mini-Review: The Contribution of Adipokines to Joint Inflammation in Inflammatory Rheumatic Diseases. <i>Frontiers in Endocrinology</i> , 2020 , 11, 606560	5.7	6
79	Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1109-1113	5.3	3
78	L5 Radiculopathy with Neurological Deficit Due To Sacral Insufficiency Fracture. <i>Journal of Rheumatology</i> , 2020 , 47, 939-940	4.1	
77	The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition. <i>Metabolites</i> , 2020 , 10,	5.6	4
76	Résistance au tocilizumab de pseudo-polyarthrites rhizomiales associées à une néoplasie : 2 cas. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020 , 87, 417-418	0.1	
75	Tocilizumab failure in malignancy-related polymyalgia rheumatica. <i>Joint Bone Spine</i> , 2020 , 87, 366-368	2.9	1
74	Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 224	5.7	11
73	An unusual association of CANOMAD and rheumatoid arthritis with a long-term follow-up. <i>Joint Bone Spine</i> , 2020 , 87, 263-264	2.9	
72	Pharmacological management of axial spondyloarthritis in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1483-1491	4	4
71	Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With Ankylosing Spondylitis. <i>Frontiers in Immunology</i> , 2018 , 9, 1610	8.4	34
70	Could Sodium Chloride be an Environmental Trigger for Immune-Mediated Diseases? An Overview of the Experimental and Clinical Evidence. <i>Frontiers in Physiology</i> , 2018 , 9, 440	4.6	12
69	Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 101-107	5.4	16

68	Unilateral Accessory Sacroiliac Joint with Bone Marrow Edema Mimicking Sacroiliitis. <i>Journal of Rheumatology</i> , 2018 , 45, 1327-1328	4.1	5
67	New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 275-282	4	5
66	Serum adipokines, adipose tissue measurements and metabolic parameters in patients with advanced radiographic knee osteoarthritis. <i>Clinical Rheumatology</i> , 2017 , 36, 2531-2539	3.9	11
65	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. <i>Autoimmunity Reviews</i> , 2017 , 16, 903-910	13.6	21
64	Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNF α therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabecular bone score. <i>European Journal of Rheumatology</i> , 2017 , 4, 189-193	1.7	7
63	Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study. <i>Journal of Rheumatology</i> , 2016 , 43, 249-50	4.1	12
62	Obituaire réponse aux agents thérapeutiques des rhumatismes inflammatoires chroniques. <i>Revue Du Rhumatisme Monographies</i> , 2016 , 83, 37-43	0	
61	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. <i>Rheumatology</i> , 2016 , 55, 291-300	3.9	103
60	Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 1153-9	4.5	38
59	Multiple paradoxical adverse events in a patient with ankylosing spondylitis treated with adalimumab. <i>European Journal of Dermatology</i> , 2016 , 26, 406-8	0.8	1
58	Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 2087-94	4.4	3
57	Paradoxical reactions under TNF α -blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. <i>RMD Open</i> , 2016 , 2, e000239	5.9	98
56	Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations. <i>Drugs and Aging</i> , 2015 , 32, 515-24	4.7	16
55	The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015 , 54, 1744-5	3.9	3
54	Sirt-1 activity in PBMC from patients with spondyloarthritis. <i>Joint Bone Spine</i> , 2015 , 82, 210-1	2.9	5
53	Effects of TNF α inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 525-32	4.1	10
52	Dysphagia Related to Esophagus Compression by Anterior Cervical Ossification in a Patient with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2015 , 42, 1922-3	4.1	5
51	Biologics in spondyloarthritis: TNF α inhibitors and other agents. <i>Immunotherapy</i> , 2015 , 7, 669-81	3.8	14

50	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. <i>Experimental Hematology and Oncology</i> , 2015 , 5, 7	7.8	9
49	Rhabdomyolysis Occurring under Statins after Intense Physical Activity in a Marathon Runner. <i>Case Reports in Rheumatology</i> , 2015 , 2015, 721078	0.8	3
48	The role of leptin in the pathophysiology of rheumatoid arthritis. <i>Life Sciences</i> , 2015 , 140, 29-36	6.8	26
47	Dysregulated serum IL-23 and SIRT1 activity in peripheral blood mononuclear cells of patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2015 , 10, e0119981	3.7	29
46	Vaccination and Induction of Autoimmune Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2015 , 14, 94-8		30
45	TNF α blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. <i>European Journal of Nutrition</i> , 2014 , 53, 951-61	5.2	40
44	Sirt1 activity in peripheral blood mononuclear cells from patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014 , 81, 462-3	2.9	9
43	Sarcoidosis induced by TNF α antagonists. Comments about the article by Vigne et al. (Joint Bone Spine 2013;80:104-7). <i>Joint Bone Spine</i> , 2014 , 81, 105-6	2.9	
42	Biological treatments given in patients with rheumatoid arthritis or ankylosing spondylitis modify HAT/HDAC (histone acetyltransferase/histone deacetylase) balance. <i>Joint Bone Spine</i> , 2014 , 81, 544-5	2.9	22
41	Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis. <i>Case Reports in Rheumatology</i> , 2014 , 2014, 949317	0.8	6
40	Relationships between Adipose Tissue and Psoriasis, with or without Arthritis. <i>Frontiers in Immunology</i> , 2014 , 5, 368	8.4	55
39	Effects of TNF α inhibitors on abdominal adiposity in patients with inflammatory rheumatic diseases. <i>Journal of Rheumatology</i> , 2014 , 41, 2491	4.1	2
38	The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2014 , 13, 121-7		19
37	Sarcoïdose induite par les anti-TNF α Commentaires \square propos l'article de Vigne C et al. (Joint Bone Spine 2013;80:104-7). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013 , 80, 631-632	0.1	1
36	Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study. <i>Frontiers in Immunology</i> , 2013 , 4, 453	8.4	39
35	Short-term efficacy of hyaluronic acid joint injections in a case of ochronotic arthropathy. <i>Journal of Clinical Rheumatology</i> , 2013 , 19, 152-3	1.1	3
34	Acute pancreatitis occurring after pamidronate infusions in two patients with spondyloarthritis. <i>Case Reports in Rheumatology</i> , 2013 , 2013, 912692	0.8	
33	Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement. <i>Patient Preference and Adherence</i> , 2013 , 7, 369-77	2.4	21

32	Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production. <i>PLoS ONE</i> , 2013 , 8, e70939	3.7	48
31	Comments on the article by Tabache F. et al. "Acute polyarthritis after influenza A H1N1 immunization", <i>Joint Bone Spine</i> , 2011, doi:10.1016/j.jbs.2011.02.007: Primary Sjögren's syndrome occurring after influenza A H1N1 vaccine administration. <i>Joint Bone Spine</i> , 2012 , 79, 107	2.9	8
30	Development of inflammatory bowel disease during anti-TNF- α therapy for inflammatory rheumatic disease: a nationwide series. <i>Joint Bone Spine</i> , 2012 , 79, 457-63	2.9	85
29	Développement d'un syndrome de Gougerot-Sjögren primitif après administration de vaccin antigrippal A/H1N1. Commentaire de l'article de F. Tabache et al. «Polyarthrite aiguë après vaccination antigrippale A/H1N1», <i>Joint Bone Spine</i> , 2011, doi:10.1016/j.jbs.2011.02.007. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012 , 78, 101-103	0.1	
28	Développement de maladies inflammatoires intestinales au cours de traitement anti-TNF- α dans les rhumatismes inflammatoires. Etude nationale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012 , 79, 323-329	0.1	
27	The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2012 , 11, 159-68		129
26	Current therapeutics for spondyloarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2469-77	4	6
25	Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature review. <i>Inflammation and Allergy: Drug Targets</i> , 2010 , 9, 51-9		21
24	Elevated adiponectin serum levels in women with systemic autoimmune diseases. <i>Mediators of Inflammation</i> , 2010 , 2010, 938408	4.3	27
23	Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies. <i>Drugs and Aging</i> , 2010 , 27, 523-31	4.7	27
22	Correspondence to the article by Park Min-Chan "Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis" <i>Joint Bone Spine</i> 2009;76:170-75. <i>Joint Bone Spine</i> , 2010 , 77, 90; author reply 91	2.9	
21	Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. <i>Joint Bone Spine</i> , 2010 , 77, 142-5	2.9	20
20	Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?. <i>Joint Bone Spine</i> , 2010 , 77, 395-8	2.9	10
19	Correspondance concernant l'article de Min-Chan Park «Effet pro-inflammatoire de la leptine sur les cellules mononucléés de sang de patients atteints de spondylarthrite ankylosante». <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010 , 77, 113-114	0.1	
18	Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. <i>Rheumatology</i> , 2009 , 48, 883-6	3.9	192
17	Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. <i>Journal of Rheumatology</i> , 2009 , 36, 2421-7	4.1	55
16	Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. <i>Arthritis Research and Therapy</i> , 2009 , 11, R101	5.7	37
15	Management of ankylosing spondylitis with infliximab. <i>Open Access Rheumatology: Research and Reviews</i> , 2009 , 1, 69-82	2.4	1

14	Epstein-Barr virus in autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008 , 22, 883-96	5.3	181
13	The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2089-107	4	56
12	Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. <i>Metabolism: Clinical and Experimental</i> , 2007 , 56, 1383-9	12.7	94
11	Relations physiopathologiques polyarthrite rhumatoïde et virus d'Epstein-Barr : État des lieux. <i>Revue Du Rhumatisme (Edition Française)</i> , 2007 , 74, 814-823	0.1	1
10	Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. <i>Joint Bone Spine</i> , 2007 , 74, 418-26	2.9	66
9	The contribution of adipose tissue and adipokines to inflammation in joint diseases. <i>Current Medicinal Chemistry</i> , 2007 , 14, 1095-100	4.3	127
8	Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2007 , 19, 340-5	5.3	37
7	Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2007 , 1, 39-47	5.4	27
6	Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. <i>Journal of Rheumatology</i> , 2006 , 33, 1027-8	4.1	31
5	Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options. <i>Drugs and Aging</i> , 2005 , 22, 451-69	4.7	34
4	Bacillus calmette-guérin vaccination in a patient treated with infliximab. <i>Journal of Rheumatology</i> , 2005 , 32, 2500-1	4.1	5
3	The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 581-94	4	73
2	Anti-TNF-alpha therapy in ankylosing spondylitis. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1497-507	4	26
1	Current guidelines for the drug treatment of ankylosing spondylitis. <i>Drugs</i> , 1998 , 56, 225-40	12.1	39